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resulted  from  the  transcriptional  acti-
vation  of LMO2,  a  known proto-onco-
gene, by enhancer sequences contained 
in the long terminal repeat (LTR) of the 
murine  leukemia  virus–derived  (MLV-
derived)  therapeutic vector  (10).  In  the 
clinic, MLV-based gene delivery systems 
are  being  progressively  supplanted  by 







































aberrant  splicing  (13,  14).  Both  studies 
were performed using lentiviral vectors and 
human cells, notably HSCs and primary 




























chimeric  transcripts  cumulatively  con-






to  demonstrate  that mutating  some  of 
these sequences could reduce the rate of 
read-through transcription, but this was 







Citation	for	this	article: J Clin Invest. 2012; 
122(5):1600–1602. doi:10.1172/JCI63066.
commentaries
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 122      Number 5      May 2012  1601
but since Mavilio and colleagues performed 
all of their analyses with SIN lentiviral vec-
tors,  this nuance gives no  real  comfort. 




























































or  acceptor  sites,  in  some  cases  gener-










Vector-induced chimeric transcripts. (A) A cellular gene producing an mRNA endowed with a regulatory miRNA target sequence at its 3ʹ end. 
Protein product is described at right. (B) The same gene, with a vector provirus integrated between two exons in the sense orientation. Two 
general categories of aberrant mRNAs are depicted as either 5ʹ (av) or 3ʹ (va/vb) fusions between vector (v) and cellular transcripts. Compared 
with its physiological counterpart (a), av mRNA yields a truncated cellular protein (potentially fused to a fragment of the transgenic protein) at 
high levels, owing to the loss of 3ʹ miRNA target sequences. va results from proviral transcriptional read-through, and vb results from the use of 
a cryptic splice donor in the vector. Only the transgenic protein is produced at significant levels from va, as translation of the cellular part of this 
transcript would require reinitiation, a very inefficient process. The resulting transcript is predicted to be expressed at low levels, irrespective of 
the presence of an miRNA target sequence, due to nonsense-mediated degradation. (C) The provirus-harboring locus, with insertion of target 
sequences for a stage-specific miRNA in the vector transcript as a safeguard. Both vector-derived (v*) and cellular-viral fusion (av*, v*a) mRNAs 
will be degraded in cells expressing the miRNA, e.g., transformation-prone stem cells, resulting in very low levels of abnormal protein. However, 
a vb-like mRNA devoid of miRNA target sequence owing to aberrant splicing would escape downregulation, as would av-like transcripts gener-
ated from a provirus integrated in the antisense orientation.
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transformation,  namely  stem  cells  and 
early precursors.  In situations  in which 
only differentiated cells  require pheno-
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Epidermal Langerhans cells tune skin reactivity  
to contact allergens
Mark C. Udey
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Skin  represents  a  dynamic,  responsive 
interface that separates organism and envi-




rier  that,  under  normal  circumstances, 




is  poised  to  respond  to  environmental 
insults that breach the skin’s physical bar-
rier. Reactivity of this immunologic barrier 
is fine tuned. Pathogenic microbes trigger 
responses that are sufficiently vigorous and 
sustained so that offending organisms are 
contained and ultimately cleared without 
